Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 5Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Myeloid 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Myeloproliferative Disorders 1

Interventions

Rituximab 21Cyclophosphamide 21fludarabine 12fludarabine phosphate 10pirtobrutinib 6obinutuzumab 6ibrutinib 6acalabrutinib 6Tacrolimus 6Mycophenolic Acid 6Melphalan 6Magnetic Resonance Spectroscopy 6Biopsy 6venetoclax 5tocilizumab 5X-Rays 5Whole-Body Irradiation 5Specimen Handling 5Prednisone 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Etoposide 5Doxorubicin 5Thiotepa 4Lenalidomide 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Cytarabine 4Bendamustine Hydrochloride 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Non-Hodgkin × parsaclisib × Clear all
NCT04661007 2026-05-18

J-MIND

Incyte Corporation

Phase 1/2 Active not recruiting
72 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Incyte Corporation

Phase 2 Active not recruiting
112 enrolled
LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡